Summary
Philip Morris International (PM) reported a solid third quarter of 2021, demonstrating robust growth in net revenues and earnings, primarily driven by strong performance in reduced-risk products (RRPs), particularly IQOS. The company saw a notable increase in net revenues to $8.12 billion for the quarter and $23.3 billion for the nine months, up 9.1% and 9.7% respectively, year-over-year. Diluted EPS also showed healthy growth, reaching $1.55 for the quarter and $4.48 for the nine months, an increase of 4.7% and 14.9% respectively. PMI's strategic transition towards smoke-free products continues to gain traction, with RRP net revenues growing 37.5% for the nine months. This growth was driven by higher heated tobacco unit volumes across key markets in Europe and Asia, coupled with favorable pricing. However, the company is facing challenges related to global semiconductor shortages, which are impacting IQOS device supply and are expected to persist into the first half of 2022, potentially hindering near-term user growth. Despite this, PMI remains optimistic about the long-term demand for its RRPs and has strategically acquired companies like Fertin Pharma and Vectura to bolster its innovation pipeline in oral and inhaled therapeutics.
Financial Highlights
49 data points| Revenue | $8.12B |
| Cost of Revenue | $2.60B |
| Gross Profit | $5.53B |
| Operating Income | $3.46B |
| Net Income | $2.43B |
| EPS (Basic) | $1.55 |
| EPS (Diluted) | $1.55 |
| Shares Outstanding (Basic) | 1.56B |
| Shares Outstanding (Diluted) | 1.56B |
Key Highlights
- 1Net revenues increased by 9.1% to $8.12 billion for the third quarter of 2021, and by 9.7% to $23.3 billion for the first nine months of 2021, compared to the prior year.
- 2Diluted EPS grew by 4.7% to $1.55 for the third quarter and by 14.9% to $4.48 for the first nine months, reflecting strong operational performance.
- 3Reduced-Risk Products (RRPs) net revenues surged by 37.5% for the nine months, indicating successful market penetration and consumer adoption.
- 4Acquisition of Fertin Pharma and Vectura Group plc in Q3 2021 strengthens PMI's capabilities in RRP development and expands its product portfolio.
- 5The company is experiencing IQOS device supply constraints due to global semiconductor shortages, which are expected to impact user growth into the first half of 2022.
- 6PMI's dividend per share increased to an annualized rate of $5.00, demonstrating a commitment to returning capital to shareholders.
- 7Net cash provided by operating activities increased by $1.3 billion to $7.9 billion for the first nine months of 2021, supported by higher net earnings and favorable currency movements.